Antibody against interferon-α 2b in serum of the patients with chronic hepatitis C and its clinical significance: A critical trial

Hepatitis Monthly

Volumn 9, Issue 2, 2009, Pages 103-109

  Wang, Jian ^a   Wang, Pingping ^a   Xiang, Guiju ^b  

^a ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Second Miner Hospital of Huainan   (China)

Author keywords

Anti IFN 2b; Hepatitis C; Interferon 2b; Treatment

Indexed keywords

ALPHA2B INTERFERON; ALPHA2B INTERFERON ANTIBODY; IMMUNOGLOBULIN G; INTERFERON ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE;

EID: 70349274230     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Akyuz F, Polat N, Kaymakoglu S, et al. Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels. World J Gastroenterol. 205;11(45):7188-91.
2. Hung CH, Lee CM, Lu SN, et al. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol. 2002;17(12):1307-11.
3. Kasahara A, Hayashi N, Mochizuki K, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepat. 2000;7(5):343-51.
4. Wang C, Pflugheber J, Sumpter R, Jr., et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003;77(7):3898-912.
5. Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36(1):211-8.
6. Mangia A, Santoro R, Piattelli M, et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol. 2002;37(1):109-16.
7. Chapel HM, Christie JM, Peach V, Chapman RW. Fiveyear follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol. 2001;99(3):320-4.
8. Fujimoto T, Tomimatsu M, Iga D, Endo H, Otsuka K. Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. J Gastroenterol Hepatol. 2008;23(8 Pt 2):e432-7.
9. Uka K, Suzuki F, Akuta N, et al. Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J Gastroenterol. 2006;41(5):470-5.
10. Murashima S, Kumashiro R, Ide T, et al. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol. 2000;62(2):185-90.
11. Penna A, Missale G, Lamonaca V, et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virusspecific T cells: functional characterization in patients with chronic hepatitis C. Hepatology. 2002;35(5):1225-36.
12. Castet V, Fournier C, Soulier A, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol. 2002;76(16):8189-99.
13. Zhang T, Lin RT, Li Y, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology. 2005;42(4):819-27.
14. Meager A. Biological assays for interferons. J Immunol Methods. 2002;261(1-2):21-36.
15. Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology. 2002; 298(1):160-73.
16. Pan CH, Yang PM, Hwang LH, et al. T-cell antigenic determinants within hepatitis C virus nonstructural protein 3 and cytokine production profiles in hepatitis C. J Viral Hepat. 2002;9(4):258-64.
17. Bacosi M, De Angelis A, Ursitti A, et al. Association of circulating CD8(+) lymphocytes to a spontaneous and interferon-alpha induced clearance of HCV. Hepatol Res. 2002;23(3):163-6.
18. Qureshi H, Arif A, Ahmed W, et al. Role of interferon anti body in predicting the response to interferon therapy in HCV patients. J Pak Med Assoc. 2007;57(12):581-3.
19. Depraetere S, Van Kerschaever E, Van Vlierberghe H, et al. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J Med Virol. 200;60(2):126-32.
20. Li ZW, Liu P, Bai H, Sun GJ, Sun J, Ma YM. [Study on the relationship between the efficacy of IFN and ribavirin on chronic hepatitis C and the anti-IFN antibodies]. Chinese Journal of Practical Internal Medicine. 2002;22(7):399-400.
21. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005; 202(2):323-35.
22. Wang J, Xiang GJ, Liu BX. Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C. World J Gastroenterol. 2003;9(4):751-4.
23. Chen L, Chen P, Fan G, Li L, Liu C. [Localization of hepatitis C virus core protein in the nucleus of peripheral blood mononuclear cells of hepatitis C patients]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002;16(1):37-9.
24. Li CP, Wang KX, Wang J, Pan BR. mIL-2R, T cell subsets & hepatitis C. World J Gastroenterol. 2002;8(2):298-300.
25. Dominguez-Villar M, Munoz-Suano A, Anaya-Baz B, et al. Hepatitis C virus core protein up-regulates anergy-related genes and a new set of genes, which affects T cell homeostasis. J Leukoc Biol. 2007; 82(5):1301-10.
26. + T-cell proliferation in patients with hepatitis C virus infection. Immunology. 2007; 121(2):283-92.